Last reviewed · How we verify

NCT06746363

The Effectiveness of High-flow Nasal Cannula After Extubation in Patients

Completed Last updated 27 December 2024
What this trial tests

trial in Post Extubation Respiratory Failure in 110 participants. Completed in 20 March 2024.

Timeline
15 June 2022
Primary endpoint
15 January 2024
20 March 2024

Quick facts

Lead sponsorChang Gung Memorial Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment110
Start date15 June 2022
Primary completion15 January 2024
Estimated completion20 March 2024
Sites1 location across Taiwan

Conditions studied

Sponsor

Chang Gung Memorial Hospital

Who can join

Eligibility, any sex, with Post Extubation Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observe the current status of prolonged mechanical ventilation (PMV) patients using high-flow nasal cannula oxygen therapy (experimental group) or traditional oxygen therapy (control group) after extubation, and compare the differences in ventilator weaning rates between the two groups. Record the ROX index (SpO2/FiO2/RR) at 2, 6, 12, and 24 hours after extubation in PMV patients and explore whether statistical methods can predict the weaning outcome within seven days. Use statistical methods to analyze whether comorbidities in the PMV population affect ventilator weaning rates.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Post Extubation Respiratory Failure

Currently open trials in the same condition.

Other Chang Gung Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06746363.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing